The KEYS trial (2022) established that which targeted agent, when added to concurrent chemoradiotherapy, improved overall survival in locally advanced cervical cancer?
- A Bevacizumab
- B Atezolizumab
- C Pembrolizumab ✓
- D Cetuximab
Correct answer: C. Pembrolizumab
Explanation
The KEYNOTE-A18 (ENGOT-cx11/GOG-3047) trial demonstrated that adding pembrolizumab (anti-PD-1) to concurrent chemoradiotherapy (cisplatin + EBRT + brachytherapy) significantly improved progression-free survival and overall survival in high-risk locally advanced cervical cancer. Bevacizumab is used in metastatic/recurrent cervical cancer (BEVERLY trial). Pembrolizumab was thus the first immunotherapy approval in this setting.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.